IMA910 Plus GM-CSF With Low-dose Cyclophosphamide Pre-treatment in Advanced Colorectal Carcinoma Patients Following a Successful 12 Week First-line Treatment With Oxaliplatin-based Chemotherapy (IMA910-101)

NCT00785122 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

92

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Carcinoma

Interventions

DRUG: Endoxana, Leukine, IMA910
DRUG: Endoxana, Leukine, IMA910, Aldara

Sponsor

Immatics Biotechnologies GmbH